MORRISVILLE, N.C., April 11, 2023 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA) announced today that Mr. Michael Kaseta, Chief Financial Officer, will provide an overview and update on the company's business during a fireside chat session at the 22nd Annual Needham Virtual Healthcare Conference.
The presentation is scheduled to begin Tuesday, April 18, 2023 at 11:00 a.m. Eastern Standard Time and can be accessed via a live webcast on the Liquidia website at https://liquidia.com/investors/events-and-presentations. An archived, recorded version of the presentation can be accessed for 30 days following the event.
About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company focused on the development and commercialization of products in pulmonary hypertension and other applications of its PRINT® Technology. The company operates through its two wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia Technologies has developed YUTREPIA™ (treprostinil) inhalation powder, an investigational drug for the treatment of pulmonary arterial hypertension (PAH). Liquidia PAH provides the commercialization for pharmaceutical products to treat pulmonary disease, such as generic Treprostinil Injection. For more information, please visit www.liquidia.com.
Contact Information for Media & Investors
Jason Adair
Senior Vice President, Corporate Development and Strategy
919.328.4400
jason.adair@liquidia.com
